Polaryx Therapeutics (NASDAQ:PLYX) Trading 4.9% Higher - Time to Buy?

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) traded up 4.9% during trading on Tuesday . The company traded as high as $6.49 and last traded at $6.47. 141,137 shares were traded during trading, a decline of 94% from the average session volume of 2,268,150 shares. The stock had previously closed at $6.17.Get Polaryx Therapeutics alerts:Analyst Upgrades and DowngradesSeparately, Maxim Group started coverage on Polaryx Therapeutics in a report on Friday, February 27th. They set a "buy" rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $10.00.Check Out Our Latest Stock Analysis on PLYXPolaryx Therapeutics Stock Up 4.9%Polaryx Therapeutics Company Profile (Get Free Report)We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.Recommended StoriesFive stocks we like better than Polaryx TherapeuticsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Polaryx Therapeutics Right Now?Before you consider Polaryx Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Polaryx Therapeutics wasn't on the list.While Polaryx Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here